Company’s 36-month beta value is 0.52.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GLMD is 1.63M, and currently, short sellers hold a 0.30% ratio of that floaft. The average trading volume of GLMD on March 25, 2025 was 875.91K shares.
GLMD) stock’s latest price update
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD)’s stock price has plunge by -10.18relation to previous closing price of 2.26. Nevertheless, the company has seen a -18.80% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-20 that TEL AVIV, Israel, March 20, 2025 /PRNewswire/ — Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced the grant of a new patent related to its lead compound, Aramchol.
GLMD’s Market Performance
GLMD’s stock has fallen by -18.80% in the past week, with a monthly drop of -24.90% and a quarterly drop of -30.00%. The volatility ratio for the week is 15.97% while the volatility levels for the last 30 days are 14.27% for Galmed Pharmaceuticals Ltd The simple moving average for the past 20 days is -2.10% for GLMD’s stock, with a -42.17% simple moving average for the past 200 days.
Analysts’ Opinion of GLMD
Many brokerage firms have already submitted their reports for GLMD stocks, with B. Riley FBR repeating the rating for GLMD by listing it as a “Neutral.” The predicted price for GLMD in the upcoming period, according to B. Riley FBR is $8 based on the research report published on May 22, 2020 of the previous year 2020.
Craig Hallum, on the other hand, stated in their research note that they expect to see GLMD reach a price target of $18. The rating they have provided for GLMD stocks is “Buy” according to the report published on February 04th, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to GLMD, setting the target price at $14 in the report published on January 30th of the previous year.
GLMD Trading at -17.90% from the 50-Day Moving Average
After a stumble in the market that brought GLMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.47% of loss for the given period.
Volatility was left at 14.27%, however, over the last 30 days, the volatility rate increased by 15.97%, as shares sank -26.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.95% lower at present.
During the last 5 trading sessions, GLMD fell by -18.80%, which changed the moving average for the period of 200-days by -54.28% in comparison to the 20-day moving average, which settled at $2.07. In addition, Galmed Pharmaceuticals Ltd saw -36.36% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GLMD
The total capital return value is set at -0.37. Equity return is now at value -37.32, with -32.78 for asset returns.
Currently, EBITDA for the company is -6.87 million with net debt to EBITDA at 1.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.03.
Conclusion
In a nutshell, Galmed Pharmaceuticals Ltd (GLMD) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
